Flag of the European Union EU Clinical Trials Register Help

Clinical trials for car-t

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   34386   clinical trials with a EudraCT protocol, of which   5573   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: car-t. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-004043-36 Sponsor Protocol Number: 004:TCELL Start Date*: 2017-04-28
    Sponsor Name:Uppsala University
    Full Title: CD19-TARGETING 3RD GENERATION CAR T CELLS FOR REFRACTORY B CELL MALIGNANCY – A PHASE II TRIAL
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001393-19 Sponsor Protocol Number: 003:TCELL Start Date*: 2014-04-08
    Sponsor Name:Uppsala university
    Full Title: CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial.
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004867-38 Sponsor Protocol Number: AUTO-LT1 Start Date*: 2018-05-18
    Sponsor Name:Autolus Limited
    Full Title: Long-term follow-up of patients previously treated with autologous T cells genetically modified with retroviral vectors.
    Medical condition: Potential malignancy in patients who received treatment with Autolus' CAR T cell therapy.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001673-14 Sponsor Protocol Number: CCTL019A2205B Start Date*: 2015-10-06
    Sponsor Name:Novartis Pharma AG
    Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy
    Medical condition: Patients who have been treated for a B cell hematological malignancy in a Novartis sponsored or supported study of CD19 directed CAR T-Cell treatment are enrolled in this study following completion...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) DE (Ongoing) ES (Ongoing) NO (Ongoing) BE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002245-29 Sponsor Protocol Number: BB2121-MM-001 Start Date*: 2018-10-02
    Sponsor Name:Celgene Corporation
    Full Title: A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
    Medical condition: Relapsed and Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067095 Multiple myeloma progression LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) BE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002849-30 Sponsor Protocol Number: CCTL019B2101J/CHP-959 Start Date*: 2017-11-16
    Sponsor Name:University of Pennsylvania
    Full Title: A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leuk...
    Medical condition: Chemotherapy resistant or refractory CD19+ B-cell Leukemia and Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10063621 Acute lymphoblastic leukaemia recurrent LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2016-004808-60 Sponsor Protocol Number: HD-CAR-1/V03 Start Date*: 2018-04-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial
    Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    20.0 100000004864 10029595 Non-Hodgkin's lymphoma NOS refractory LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000264-28 Sponsor Protocol Number: bb2121-MM-002 Start Date*: 2018-10-19
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multi-cohort, Open-label, Multi-center Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multi...
    Medical condition: Relapsed and Refractory Multiple Myeloma and High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    20.0 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000929-32 Sponsor Protocol Number: JCAR017-BCM-003 Start Date*: 2018-08-01
    Sponsor Name:Celgene Corporation
    Full Title: A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressi...
    Medical condition: Transplant-eligible relapsed or refractory (R/R) aggressive B-cell Non Hodgkin Lymphoma (B-NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029593 Non-Hodgkin's lymphoma NOS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005007-86 Sponsor Protocol Number: KTE-C19-101 Start Date*: 2016-12-15
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1)
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B cell lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10036711 Primary mediastinal large B-cell lymphomas HLT
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001246-34 Sponsor Protocol Number: JCAR017-BCM-004 Start Date*: 2018-09-18
    Sponsor Name:Celgene Corporation
    Full Title: A phase 1B/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL
    Medical condition: Relapsed or refractory (r/r) CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029593 Non-Hodgkin's lymphoma NOS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Temporarily Halted) ES (Temporarily Halted) IT (Temporarily Halted) BE (Ongoing) NL ()
    Trial results: (No results available)
    EudraCT Number: 2016-001706-42 Sponsor Protocol Number: JCAR015-ALL-001 Start Date*: 2016-11-16
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Open-Label, Multiple Cohort, Single-Arm, Multi-Center Trial To Determine The Safety, Feasibility, And Efficacy Of JCAR015 In Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
    Medical condition: B-cell Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000106-38 Sponsor Protocol Number: JCAR017-BCM-001 Start Date*: 2018-06-14
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCEND WORLD)
    Medical condition: Aggressive B-cell Non Hodgkin Lymphoma (B-NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029593 Non-Hodgkin's lymphoma NOS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) FI (Ongoing) ES (Restarted) DE (Temporarily Halted) AT (Restarted) NL (Ongoing) GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2018-003118-42 Sponsor Protocol Number: D419EC00001 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patien...
    Medical condition: Advanced Solid Tumors and Hematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10065143 Malignant solid tumour LLT
    20.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL ()
    Trial results: (No results available)
    EudraCT Number: 2016-004682-11 Sponsor Protocol Number: AUTO3-DB1 Start Date*: 2017-07-19
    Sponsor Name:Autolus Limited
    Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 and Consolidation with Anti PD-1 Antibo...
    Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL) and large B cell lymphoma subsets
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    20.0 100000004851 10036711 Primary mediastinal large B-cell lymphomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036710 Primary mediastinal large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002475-26 Sponsor Protocol Number: GD2CAR01 Start Date*: 2017-12-22
    Sponsor Name:IRCCS Ospedale Pediatrico Bambino Gesù
    Full Title: Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma
    Medical condition: High Risk and/or relapsed/refractory Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019260 Heart block AV third degree LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005008-27 Sponsor Protocol Number: KTE-C19-102 Start Date*: 2016-12-15
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)
    Medical condition: Relapsed/Refractory Mantle Cell Lymphoma (MCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004680-39 Sponsor Protocol Number: AUTO3-PA1 Start Date*: 2017-06-21
    Sponsor Name:Autolus Limited
    Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients ...
    Medical condition: Acute lymphoblastic leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001912-13 Sponsor Protocol Number: KTE-C19-105 Start Date*: 2018-04-24
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (ZUMA-5)
    Medical condition: Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (r/r) iNHL.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001965-26 Sponsor Protocol Number: AUTO4-TL1 Start Date*: 2018-02-01
    Sponsor Name:Autolus Ltd
    Full Title: A SINGLE ARM, OPEN-LABEL, MULTI-CENTRE, PHASE I/II STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF AUTO4, A CAR T CELL TREATMENT TARGETING TRBC1, IN PATIENTS WITH RELAPSED OR REFRACTORY TRBC1 ...
    Medical condition: Relapsed or refractory T cell Non-Hodgkin Lymphoma (T-NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-Sat Mar 23 12:34:30 GMT 2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA